EuroTEST
Working together for integrated testing and earlier care

HepHIV 2026
by EuroTEST
2-3 NOVEMBER · DUBLIN

Test2Know

Effectiveness of an online home-based self-sampling platform for HIV/STI testing in Belgium

Results from the Test2Know pilot (Phase C)

Tom Platteau on behalf of Irith De Baetselier and the T2K team | HepHIV 2026

Disclosure

No conflicts of interest

Meet Test2Know

Personalised, home-based HIV/STI self-sampling



Only for asymptomatic at-risk individuals
behaviorally at risk for HIV/STI and not in follow-up (no PrEP users)

Personalised test kit
Follows ITM testing guidelines (diagnostic stewardship)
HIV, syphilis, Hepatitis C, Chlamydia, Gonorrhea

Efficient testing
fewer unnecessary Chlamydia/Gonorrhea and syphilis/HCV tests

Linkage to care
all positive results proactively contacted

www.test2know.eu

Figure made via biorender

Differences with commercial platforms

A personalized alternative to universal testing



Universal testing strategy:
tests for all pathogens → **drives up costs and risks overtreatment** in an era of rising antimicrobial resistance



Active linkage to care is often missing.

Study overview – Socio-demographic results

The aim of the study was to evaluate whether the T2K platform will be an effective online intervention to screen for HIV/STI among 500 users in Flanders, Belgium

February–September 2025 | 538 test kits shipped throughout Flanders

Participants aged 18–69 years • Median age: 36 years

Gender



- Men 65%
- Women 34%
- Non-binary 1%

Sexual orientation



- Heterosexual 70%
- MSM 18%
- Bisexual 12%

Ever tested HIV/STI



- Yes 67%
- No 33%

Results

Sexual Behavior associated with increased risk for HIV/STI

Within the last 6 months did you…

- **Have sex under the influence of drugs?**
- **Received/provided benefits for sex?**
- **Have group sex?**
- **Go to sex venues?**
- **Have more than 5 sexual partners?**



Only the following drugs during sex were taken into account: XTC/ MDMA, Cocaine, Designer drugs, Ketamine, Amphetamine, GHB/GBL

Results – personalized, risk-based testing algorithm

Following ITM testing guidelines

HIV
Always tested, except when known HIV positive

Syphilis
Effectively targeting MSM and individuals reporting sexual risk

HCV
Only tested when a sexual risk factor has been reported

Chlamydia/Gonorrhea
Guideline-concordant exclusion of exclusive MSM without transactional sex

Risk-Based Testing Algorithm Personalization Avoided:



Results

Test kits shipped



538

test kits shipped

Kits returned



72,5% return rate
(users paid €30)

First-time testers



1 in 3

were first-time testers
(33.6%)

Overall STI positivity



of returned
kits
had an STI

STI positivity in first-time testers



9.2%

of first-time testers
had an STI

28 STIs

19 Chlamydia
1 Gonorrhea

8 Active syphilis
All MSM

No HIV
No HCV

Results

Higher STI positivity rates in selected groups

Participants via Partner notification

25.7%
STI positivity rate



Men who have sex with men (MSM)

13.3%
STI positivity rate



Results

User experience and future HIV/STI testing preferences

User satisfaction

87.2%

User satisfaction score

★★★★★

Participants valued anonymity, clear instructions and rapid delivery.

Preferred testing modelapproach



- At home only: 69.7%
- Combination: 28.2%
- Physician only: 1.4%

Percentages as reported in the survey.

Discussion

Key findings from the Test2Know pilot

1. Reached participants throughout Flanders
2. One in three participants had never been tested for HIV/STIs
3. Overall positivity was 7.2%; 42.9% of diagnoses were among first-time testers
4. Positivity was particularly high following partner notification
5. **A larger study is needed to evaluate effectiveness, costs and implementation**

Thank you

to all participants, study- and laboratory staff

ViiV Healthcare

GILEAD

MSD

ANTWERP DINER®